Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas

References

• Wood TB, Spivey WTN, Easterfield TH. Cannabinol part I. J Chem Soc. 1899;75:20–36.
   Google Scholar
• Adams R, Baker BR, Wearn RB. Structure of cannabinol. III. Synthesis of cannabinol, 1-hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran. J Am Chem Soc. 1940;62:2204–2207.
   Google Scholar
• Jacob A, Todd AR. Cannabis indica. Part II. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol. J Chem Soc. 1940;(0):649–653.
   Google Scholar
• Mechoulam R, Shvo Y, Hashish I. The structure of cannabidiol. Tetrahedron. 1963;19(12):2073–2078.
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646–1647.
   Web of Science ®Google Scholar
• Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol. 2003;2(5):291–298.
   PubMed Web of Science ®Google Scholar
• Engels FK, De Jong FA, Mathijssen RHJ, et al. Medicinal cannabis in oncology. Eur J Cancer. 2007;43(18):2638–2644.
   PubMed Web of Science ®Google Scholar
• Parmar JR, Forrest BD, Freeman RA. Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Res Social Adm Pharm. 2016;12(4):638–654.
   PubMed Web of Science ®Google Scholar
• Ward SJ, McAllister SD, Kawamura R, et al. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014;171(3):636–645.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Golub V. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357(1):45–55.
   PubMed Web of Science ®Google Scholar
• Sarfaraz S, Adhami VM, Syed DN, et al. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 2008;68(2):339–342.
   PubMed Web of Science ®Google Scholar
• Munson AE, Harris LS, Friedman MA, et al. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 1975;55(3):597–602.
   PubMedGoogle Scholar
• Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745–755.
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–1949.
   PubMed Web of Science ®Google Scholar
• Felder CC, Briley EM, Axelrod J, et al. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci. 1993;90(16):7656–7660.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89–97.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90.
   PubMed Web of Science ®Google Scholar
• Malfitano AM, Basu S, Maresz K, et al. What we know and do not know about the cannabinoid receptor 2 (CB2). Sem in Immunol. 2014;26(5):369–379.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Howell F, Williams G, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163(3):463–468.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Melck D, De Petrocellis L, et al. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J Neurochem. 1999;72(5):2113–2119.
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604):83–87.
   PubMed Web of Science ®Google Scholar
• Tsuboi K, Takezaki N, Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers. 2007;4(8):1914–1925.
   PubMed Web of Science ®Google Scholar
• Ueda N, Tsuboi K, Uyama T. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res. 2010;49(4):299–315.
   PubMed Web of Science ®Google Scholar
• Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev. 2011;111(10):5899–5921.
   PubMed Web of Science ®Google Scholar
• Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99(16):10819–10824.
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Muccioli GG. COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci. 2014;35(6):284–292.
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Masquelier J, Muccioli GG. Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy. Drug Discov Today. 2014;19(3):295–304.
   PubMed Web of Science ®Google Scholar
• Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacol Biochem Behav. 2008;90(4):501–511.
   PubMed Web of Science ®Google Scholar
• Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(1):4–15.
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–564.
   PubMed Web of Science ®Google Scholar
• Hirst RA, Lambert DG, Notcutt WG. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth. 1998;81(1):77–84.
   PubMed Web of Science ®Google Scholar
• Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: A systematic review. Autoimmun Rev. 2016;15(6):513–528.
   PubMed Web of Science ®Google Scholar
• Szulakowska A, Milnerowicz H. Cannabis sativa in the light of scientific research. Adv Clin Exp Med. 2007;16(6):807–815.
   Web of Science ®Google Scholar
• Munro S, Thomas KL, Abushaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65.
   PubMed Web of Science ®Google Scholar
• Velasco G, Galve-Roperh I, Sanchez C, et al. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacol. 2004;47(3):315–323.
   PubMed Web of Science ®Google Scholar
• Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci. 2006;1074:514–536.
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329–332.
   PubMed Web of Science ®Google Scholar
• Navarrete F, Perez-Ortiz JM, Manzanares J. Cannabinoid CB₂ receptor-mediated regulation of impulsive-like behaviour in DBA/2 mice. Br J Pharmacol. 2012;165(1):260–273.
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62(4):588–631.
   PubMed Web of Science ®Google Scholar
• Lu H.C., Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–525.
   PubMed Web of Science ®Google Scholar
• Petersen G, Moesgaard B, Schmid PC, et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J Neurochem. 2005;93(2):299–309.
   PubMed Web of Science ®Google Scholar
• Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125(3):677–687.
   PubMed Web of Science ®Google Scholar
• Schmid PC, Wold LE, Krebsbach RJ, et al. Anandamide and other N-acylethanolamines in human tumors. Lipids. 2002;37(9):907–912.
   PubMed Web of Science ®Google Scholar
• Endsley MP, Thill R, Choudhry I, et al. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer. 2008;123(6):1318–1326.
   PubMed Web of Science ®Google Scholar
• Thors L, Bergh A, Persson E, et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. Plos One. 2010;5(8):e12275.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Long JZ, Niessen S, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140(1):49–61.
   PubMed Web of Science ®Google Scholar
• Van Dross R, Soliman E, Jha S, et al. Receptor-dependent and receptor-independent endocannabinoid signaling: A therapeutic target for regulation of cancer growth. Life Sci. 2013;92(8–9):463–466.
   PubMed Web of Science ®Google Scholar
• Cipriano M, Gouveia-Figueira S, Persson E, et al. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. BMC Res Notes. 2014;7:441–448.
   PubMedGoogle Scholar
• Caffarel MM, Andradas C, Mira E, et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010;9:196.
   PubMed Web of Science ®Google Scholar
• Perez-Gomez E, Andradas C, Blasco-Benito S, et al. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. J Natl Cancer Inst. 2015;107(6):djv077.
   PubMedGoogle Scholar
• Prather PL, FrancisDevaraj F, Dates CR, et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Commun. 2013;441(2):339–343.
   PubMed Web of Science ®Google Scholar
• Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005;65(5):1635–1641.
   PubMed Web of Science ®Google Scholar
• Orellana-Serradell O, Poblete CE, Sanchez C, et al. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep. 2015;33(4):1599–1608.
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez E, Gomez I, Martin P, et al. Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience. 2015;2(2):131–141.
   PubMedGoogle Scholar
• Sánchez C, De Ceballos ML, Gomez Del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001;61(15):5784–5789.
   PubMed Web of Science ®Google Scholar
• Michalski CW, Oti FE, Erkan M, et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer. 2008;122(4):742–750.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171(1):31–38.
   PubMed Web of Science ®Google Scholar
• Theocharis S, Giaginis C, Alexandrou P, et al. Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients’ survival. Tumour Biol. 2016;37(3):3647–3656.
   PubMed Web of Science ®Google Scholar
• Messalli EM, Grauso F, Luise R, et al. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am J Obstet Gynecol. 2014;211(3):234.e1–234-e6.
   PubMed Web of Science ®Google Scholar
• Coke CJ, Scarlett KA, Chetram MA, et al. Simultaneous activation of induced heterodimerization between CXCR4 chemokine receptor and cannabinoid receptor 2 (CB2) reveal a mechanism for regulation of tumor progression. J Biol Chem. 2016;291(19):9991–10005.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Borselli C, Oliviero O, et al. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol. 2007;211(2):495–503.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Josefsson A, Thors L, et al. Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer. Biochim Biophys Acta. 2013;1831(10):1579–1587.
   PubMed Web of Science ®Google Scholar
• Haggstrom J, Cipriano M, Forshell LP, et al. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray. Prostate. 2014;74(11):1107–1117.
   PubMed Web of Science ®Google Scholar
• Arnold JC, Hone P, Holland ML, et al. CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep. 2012;64(3):751–757.
   PubMed Web of Science ®Google Scholar
• Holland ML, Panetta JA, Hoskins JM, et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol. 2006;71(8):1146–1154.
   PubMed Web of Science ®Google Scholar
• Feinshtein V, Erez O, Ben-Zvi Z, et al. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ. 2013;1:e153.
   Google Scholar
• Singer E, Judkins J, Salomonis N, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 2015;6:e1601.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Katayama K, Melck D, et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells implications for cell proliferation and differentiation. Eur J Biochem. 1998;254(3):634–642.
   PubMedGoogle Scholar
• Melck D, Petrocellis L, Orlando P, et al. Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000;141(1):118–126.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A. 1998;95(14):8375–8380.
   PubMed Web of Science ®Google Scholar
• Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318(3):1375–1387.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Kuzontkoski PM, Groopman JE, et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10(7):1161–1172.
   PubMed Web of Science ®Google Scholar
• Caffarel MM, Sarrio D, Palacios J, et al. Delta(9)-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006;66(13):6615–6621.
   PubMed Web of Science ®Google Scholar
• Elbaz M, Nasser MW, Ravi J, et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol. 2015;9(4):906–919.
   PubMed Web of Science ®Google Scholar
• McAllister SD, Christian RT, Horowitz MP, et al. Cannabidiol as a novel inhibitor of ld-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007;6(11):2921–2927.
   PubMed Web of Science ®Google Scholar
• McAllister SD, Murase R, Christian RT, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011;129(1):37–47.
   PubMed Web of Science ®Google Scholar
• Grimaldi C, Pisanti S, Laezza C, et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res. 2006;312(4):363–373.
   PubMed Web of Science ®Google Scholar
• Laezza C, Pisanti S, Crescenzi E, et al. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett. 2006;580(26):6076–6082.
   PubMed Web of Science ®Google Scholar
• Laezza C, Pisanti S, Malfitano AM, et al. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer. 2008;15(4):965–974.
   PubMed Web of Science ®Google Scholar
• Rudolph MI, Boza Y, Yefi R, et al. The influence of mast cell mediators on migration of SW756 cervical carcinoma cells. J Pharmacol Sci. 2008;106(2):208–218.
   PubMed Web of Science ®Google Scholar
• Laezza C, d’Alessandro A, Malfitano AM, et al. Anandamide inhibits the Wnt/beta-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur J Cancer. 2013;49(8):2066–2067.
   PubMed Web of Science ®Google Scholar
• Picardi P, Ciaglia E, Proto M, et al. Anandamide inhibits breast tumor-induced angiogenesis. Transl Med UniSa. 2014;10:8–12.
   PubMedGoogle Scholar
• Emery SM, Alotaibi MR, Tao Q, et al. Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells. J Pharmacol Exp Ther. 2014;348(2):293–302.
   PubMed Web of Science ®Google Scholar
• Qamri Z, Preet A, Nasser MW, et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009;8(11):3117–3129.
   PubMed Web of Science ®Google Scholar
• Morales P, Blasco-Benito S, Andradas C, et al. Selective, nontoxic CB2 Cannabinoid o-Quinone with in vivo activity against triple-negative breast cancer. J Med Chem. 2015;58(5):2256–2264.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Isbell MA, Endsley MP, et al. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat. 2011;94(1–2):34–43.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Pommery N, Wattez N, et al. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 2003;56(1):1–12.
   PubMed Web of Science ®Google Scholar
• Endsley MP, Aggarwall N, Isbell MA, et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer. 2007;121(5):984–991.
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Endsley MP, Isbell MA, et al. 2-arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004;64(24):8826–8830.
   PubMed Web of Science ®Google Scholar
• Ruiz L, Miguel A, Dı́az-Laviada I. Δ9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 1999;458(3):400–404.
   PubMed Web of Science ®Google Scholar
• Sreevalsan S, Joseph S, Jutooru I, et al. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res. 2011;31(11):3799–3807.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Ligresti A, Schiano Moriello A, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013;168(1):79–102.
   PubMed Web of Science ®Google Scholar
• Olea-Herrero N, Vara D, Malagarie-Cazenave S, et al. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2. Br J Cancer. 2009;101(6):940–950.
   PubMed Web of Science ®Google Scholar
• Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem. 2006;281(51):39480–39491.
   PubMed Web of Science ®Google Scholar
• Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004;64(6):1943–1950.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Galve-Roperh I, Canova C, et al. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 1998;436(1):6–10.
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174(6):3281–3289.
   PubMed Web of Science ®Google Scholar
• Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165(1):373–380.
   PubMed Web of Science ®Google Scholar
• Sanchez MG, Sanchez AM, Ruiz-Llorente L, et al. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett. 2003;555(3):561–566.
   PubMed Web of Science ®Google Scholar